References (continued)

30. Sennino B, Naylor R, Tabruyn S, et al. Abstract A13: reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184 – Sennino et al. 8 (1001): A13 – molecular cancer therapeutics. Mol Cancer Ther. 2009;8:A13.

Continue Reading

31. Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs. 2010;13(2):112–124.

32. You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011;71(14):4758–4768.

33. Miyata Y, Asai A, Mitsunari K, et al. Met in urological cancers. Cancers (Basel). 2014;6(4):2387–2403.

34. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001;158:1111–1120.

35. Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998;97:381–390.

36. Ono K, Kamiya S, Akatsu T, et al. Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line BALB/c-MC. Bone. 2006;39(1):27–34.

37. Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep. 2013;15(2):76–82.

38. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299–309.

39. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in suni-tinib-resistant tumors. Cancer Res. 2010;70:10090–10100.

40. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–239.

41. Di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape. Cancer Res. 2011;71:19–28.

42. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–2350.

43. Trusolino L, Pugliese L, Comoglio PM. Interactions between scatter factors and their receptors: hints for therapeutic applications. FASEB J. 1998;12:1267–1280.

44. Sun Y, Sun L, An Y, Shen X. Cabozantinib, a novel c-met inhibitor, inhibits colorectal cancer development in a xenograft model. Med Sci Monit. 2015;21:2316–2321.

45. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;2(3):270–287.

46. Navis AC, Bourgonje A, Wesseling P, et al. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS One. 2013;8(3).

47. Torres KE, Zhu QS, Bill K, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17:3943–3955.

48. Roland CL, Dineen SP, Lynn KD, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther. 2009;8:1761–1771.

49. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9:1544–1553.

50. Castellone MD, Carlomagno F, Salvatore G, Santoro M. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endo-Crinol Metab. 2008;22:1023–1038.

51. Timar J, Dome B. Antiangiogenic drugs and tyrosine kinases. Anti-Cancer Agents Med Chem. 2008;8:462–469.

52. Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014;25(8):1603–1608.

53. Durante C, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs. 2011;20(3):407–413.

54. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646.

55. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. 2011 ASCO Annual Meeting Abstracts Part 1. 2011:4516. J Clin Oncol. 29, No 15_suppl (May 20 Supplement).

56. Smith MR, De Bono JS, Sternberg CN, et al. Final analysis of COMET-1: cabozantinib versus prednisone in metastatic castration-resistant prostate cancer patients previously treated with docetaxel and abiraterone and/or enzalutamide. Proceedings of the 2015 Genitourinary Cancers Symposium. Presented February 26, 2015. Chicago, Illinois: 2015. J Clin Oncol. 33, 2015 (suppl 7; abstr 139).

57. Basch EM, Scholz MC, De Bono JS, et al. Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). In: J Clin Oncol. 2015 Genitourinary Cancers Symposium; February 26–28, 2015. Orlando, Florida. 2015;33(Suppl 7), abstract 14.

58. Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927.

59. Schoffski P, Elisei R, Muller S, Brose MS, Shah MH, Licitra LF. In an international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid cancer (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol. 2012;30:5508.

60. Klein Hesselink EN, Steenvoorden D, Kapiteijn E, et al. Therapy of endocrine disease: response and toxicity of small molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2015;172(5):R215–R225.

61. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412–419.

62. Leibowitz-Amit R, Pintilie M, Khoja L, et al. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. J Transl Med. 2016;14:12.

63. Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013;19(11):3088–3094.

64. [webpage on the Internet]. Cabozantinib-s-malate or Sunitinib Malate in treating patients with previously untreated locally advanced or metastatic kidney cancer. 2016. Available from: Accessed May 29, 2016.

65. Nguyen L, Benrimoh N, Xie Y, Offman E, Lacy S. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs. 2016;27(7):669–678.

66. Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand–foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol. 2016;41(1):8–15.

67. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084–1089.

68. Bracarda S, Iacovelli R, Boni L, et al; Rainbow Group. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26(10):2107–2113.

69. Kalra S, Rini BI, Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1300–1304.

70. Kondo T, Takagi T, Kobayashi H, et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma–comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol. 2014;44(3):270–277.

71. Guida FM, Santoni M, Conti A, et al. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2014;92(3):208–217.

72. [webpage on the Internet]. Cabozantinib-s-malate and nivolumab with or without ipilimumab in treating patients with metastatic genitourinary tumors. 2016. Available from: Accessed May 29, 2016.

73. Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.

74. Apolo AB, Tomita Y, Lee M-J, et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. ASCO Annual Meeting. 2014. J Clin Oncol. 32:5s, 2014 (suppl; abstr 4501).

75. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473.

76. [webpage on the Internet]. Cabozantinib-S-malate, crizotinib, volitinib, or sunitinib malate in treating patients with locally advanced or metastatic kidney cancer. 2016. Available from: Accessed May 29, 2016.

77. Haas NB, Manola J, Uzzo RG, et al. Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. Proceedings of the 2015 Genitourinary Cancers Symposium. Presented February 26, 2015. Chicago, Illinois: 2015. J Clin Oncol. 33, 2015 (suppl 7; abstr 403).

78. [webpage on the Internet]. Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney. 2016. Available from: Accessed May 29, 2016.

79. [webpage on the Internet]. Adjuvant axitinib therapy of renal cell cancer in high risk patients (ATLAS). 2016. Available from: Accessed May 29, 2016.

80. [webpage on the Internet]. A clinical trial comparing efficacy and safety of sunitinib versus placebo for thetreatment of patients at high risk of recurrent renal cell cancer (S-TRAC). 2016. Available from: Accessed May 29, 2016.

81. [webpage on the Internet]. Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions. 2016. Available from: Accessed May 29, 2016.

82. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–186.

83. Yin X, Zhang T, Su X, et al. Relationships between chromosome 7 gain, MET gene copy number increase and MET protein overexpression in Chinese papillary renal cell carcinoma patients. PLoS One. 2015;10(12):e0143468.

84. Apollo AB, Tomita Y, Lee M-J, et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma [abstract]. Proceedings of 2014 American Society of Clinical Oncology, 2014, May 30th to June 3rd. Chicago, Illinois: ASCO; 2014:Abstract nr4501.

85. Exelixis, Inc. 2016 [homepage on the internet]. Available from: Accessed September 20, 2016.